Immune checkpoint inhibitor-induced diabetes mellitus: A review of mechanisms, clinical features, and therapeutic approaches.
Abstract
Since the FDA approval of ipilimumab in 2011, immune checkpoint inhibitors (ICIs) have reshaped the paradigm of cancer treatments. This has been pursued with the development and clinical investigation of combination immunotherapies with multiple ICIs. However, more than 20% of recipients of ICI monotherapy and a higher proportion of those who receive combination immunotherapy experience high-grade immune-related adverse events (irAEs). Checkpoint inhibitor-induced diabetes mellitus (CPI-DM) is a rare endocrine irAE, with an incidence rate of 0.2-3.5%, manifesting similarly to T1DM in most cases. Unlike other endocrine irAEs, CPI-DM is generally unresponsive to steroids and requires lifelong insulin treatment, hence exerting considerable morbidity on affected patients. The disruption of PD-1/PD-L1-mediated peripheral tolerance, the emergence of autoantibodies, INF-γ-driven inflammation, and cytotoxic T-cell- and pro-inflammatory monocyte/macrophage-mediated tissue destruction, under the shadow of genetic susceptibilities, are proposed to be central to CPI-DM pathogenesis. However, the pathogenic mechanisms and the management strategies of irAEs remain incompletely understood, and this review aims to summarize molecular and cellular events that underpin the development of CPI-DM, as well as its clinical presentations and novel, cell- and molecule-based preventive and therapeutic strategies.